Literature DB >> 11174334

Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.

Y Inokubo1, H Hanada, H Ishizaka, T Fukushi, T Kamada, K Okumura.   

Abstract

BACKGROUND: Previous studies on atherectomy specimens from patients with acute coronary syndrome (ACS) implicated the role of proteolytic enzymes. We examined whether the plasma levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were increased in the coronary circulation in ACS. METHODS AND
RESULTS: The plasma levels (nanograms per milliliter) of MMP-9 and TIMP-1 in the aorta (Ao) and great cardiac vein (GCV) were measured in 29 patients with ACS (20 with acute myocardial infarction [group 1] and 9 with unstable angina [group 2]), 17 with stable effort angina (group 3), and 20 control subjects (group 4). Group 1 patients had occlusion in the left anterior descending artery (LAD), and groups 2 and 3 patients had culprit lesion in the LAD. In group 1 blood samples were obtained at the time of direct coronary angioplasty done within 12 hours after the onset. The Ao level of either MMP-9 or TIMP-1 did not differ among the 4 groups. The GCV-Ao differences in MMP-9 and TIMP-1 were both significantly increased in groups 1 and 2 compared with those in group 4. Neither of them was different between groups 3 and 4. Neither the GCV-Ao difference in MMP-9 or TIMP-1 level was correlated with the maximal creatine kinase level in group 1.
CONCLUSIONS: Increased plasma levels of MMP-9 and TIMP-1 were detected in the coronary circulation in ACS patients, suggesting a process of active plaque rupture in ACS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174334     DOI: 10.1067/mhj.2001.112238

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  48 in total

1.  Tipping the extracellular matrix balance during heart failure progression: do we always go right?

Authors:  Ying Ann Chiao; Yu-Fang Jin; Merry L Lindsey
Journal:  Cardiology       Date:  2010-07-02       Impact factor: 1.869

2.  Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.

Authors:  Ulf Diekmann; Ralf Zarbock; Doris Hendig; Christiane Szliska; Knut Kleesiek; Christian Götting
Journal:  J Mol Med (Berl)       Date:  2009-07-03       Impact factor: 4.599

3.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

4.  Association of rs5368 and rs3917406 polymorphisms in E-selectin gene with premature coronary artery disease in Chinese Han population.

Authors:  Hongwei Shan; Min Zhang; Mingduo Zhang; Xin Liu; Xiantao Song; Xunli Yin; Shuzheng Lv
Journal:  Int J Clin Exp Med       Date:  2015-03-15

5.  Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain.

Authors:  Chun Gu; Fang Wang; Zhihui Hou; Bin Lv; Yang Wang; Xiangfeng Cong; Xi Chen
Journal:  Heart Vessels       Date:  2017-07-19       Impact factor: 2.037

6.  Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction.

Authors:  Takayuki Fujiwara; Toshiro Matsunaga; Kunihiko Kameda; Naoki Abe; Hirotsugu Ono; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Tomohiro Osanai; Ken Okumura
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

7.  Inflammageing assessed by MMP9 in normal Japanese individuals and the patients with Werner syndrome.

Authors:  Makoto Goto; Junji Chiba; Masaaki Matsuura; Sachiko Iwaki-Egawa; Yasuhiro Watanabe
Journal:  Intractable Rare Dis Res       Date:  2016-05

8.  Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages.

Authors:  Yoshimi Kishimoto; Mariko Tani; Harumi Uto-Kondo; Maki Iizuka; Emi Saita; Hirohito Sone; Hideaki Kurata; Kazuo Kondo
Journal:  Eur J Nutr       Date:  2009-09-26       Impact factor: 5.614

Review 9.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

10.  Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients.

Authors:  José A Páramo; José A Rodríguez Ja; Josune Orbe
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.